Dynamic Pharmacogenetic Models in Anticoagulation Therapy

Clinics in Laboratory Medicine

Volumn 28, Issue 4, 2008, Pages 539-552

  Homme, Marjorie Bon ^a   Reynolds, Kristen K ^a,b   Valdes Jr , Roland ^a   Linder, Mark W ^a  

^a University of Louisville School of Medicine   (United States)

^b PGXL Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ANTICOAGULANT THERAPY; BIOINFORMATICS; DECISION SUPPORT SYSTEM; DRUG CLEARANCE; ENANTIOMER; ETHNICITY; GENOTYPE; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORBIDITY; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DECISION SUPPORT SYSTEMS, CLINICAL; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; MODELS, THEORETICAL; PHARMACOGENETICS; POLYMORPHISM, GENETIC; WARFARIN;

EID: 57049126268     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2008.10.002     Document Type: Review

References (52)

1. Budnitz D.S., Pollock D.A., Weidenbach K.N., et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296 15 (2006) 1858-1866
2. Budnitz D.S., Shehab N., Kegler S.R., et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 147 11 (2007) 755-765
3. McWilliam A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing: the case of warfarin: AEI-Brookings Joint Center for Regulatory Studies; 2006.
4. Zhu Y., Shennan M., Reynolds K.K., et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 53 7 (2007) 1199-1205
5. D'Andrea G., D'Ambrosio R.L., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 2 (2005) 645-649
6. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 22 (2005) 2285-2293
7. Sconce E.A., Khan T.I., Wynne H.A., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 7 (2005) 2329-2333
8. Veenstra D.L., You J.H., Rieder M.J., et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 15 10 (2005) 687-691
9. Yuan H.Y., Chen J.J., Lee M.T., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14 13 (2005) 1745-1751
10. Bodin L., Verstuyft C., Tregouet D.A., et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106 1 (2005) 135-140
11. Reynolds KK, Gage BF, Silvestrov NA, et al. Accuracy of genotype-based warfarin dose estimation and plasma S-warfarin pharmacokinetic modeling. Paper presented at the American Association of Clinical Chemistry Annual Meeting. Washington, DC; 2008.
12. Takahashi H., and Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 40 8 (2001) 587-603
13. Kirchheiner J., and Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77 1 (2005) 1-16
14. Scordo M.G., Pengo V., Spina E., et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72 6 (2002) 702-710
15. Schelleman H., Chen Z., Kealey C., et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 81 5 (2007) 742-747
16. Schelleman H., Limdi N.A., and Kimmel S.E. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 9 9 (2008) 1331-1346
17. Fihn S.D., McDonell M., Martin D., et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 118 7 (1993) 511-520
18. Landefeld C.S., and Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95 3 (1993) 315-328
19. Fennerty A., Dolben J., Thomas P., et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) 288 6426 (1984) 1268-1270
20. Tait R.C., and Sefcick A. A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation. Br J Haematol 101 3 (1998) 450-454
21. Harrison L., Johnston M., Massicotte M.P., et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126 2 (1997) 133-136
22. Vigano S., Mannucci P.M., Solinas S., et al. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 57 2 (1984) 213-220
23. Harper P., Monahan K., and Baker B. Warfarin induction at 5 mg daily is safe with a low risk of anticoagulant overdose: results of an audit of patients with deep vein thrombosis commencing warfarin. Intern Med J 35 12 (2005) 717-720
24. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 204S-233S
25. Cooper M.W., and Hendra T.J. Prospective evaluation of a modified Fennerty regimen for anticoagulating elderly people. Age Ageing 27 5 (1998) 655-656
26. Garcia D., Regan S., Crowther M., et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 127 6 (2005) 2049-2056
27. Gedge J., Orme S., Hampton K.K., et al. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 29 1 (2000) 31-34
28. O'Connell M.B., Kowal P.R., Allivato C.J., et al. Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy 20 8 (2000) 923-930
29. Roberts G.W., Druskeit T., Jorgensen L.E., et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Aust N Z J Med 29 5 (1999) 731-736
30. Siguret V., Gouin I., Debray M., et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med 118 2 (2005) 137-142
31. *3/4 genotype with extremely low warfarin dose requirement. J Korean Med Sci 22 3 (2007) 557-559
32. Ageno W., Turpie A.G., Steidl L., et al. Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. Am J Cardiol 88 1 (2001) 40-44
33. Rahman M., BinEsmael T.M., Payne N., et al. Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother 40 3 (2006) 397-401
34. Oates A., Jackson P.R., Austin C.A., et al. A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 46 2 (1998) 157-161
35. Poller L., Shiach C.R., MacCallum P.K., et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 352 9139 (1998) 1505-1509
36. Ageno W., Johnson J., Nowacki B., et al. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy. Thromb Haemost 83 6 (2000) 849-852
37. Vadher B.D., Patterson D.L., and Leaning M.S. Validation of an algorithm for oral anticoagulant dosing and appointment scheduling. Clin Lab Haematol 17 4 (1995) 339-345
38. Wadelius M., Chen L.Y., Downes K., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5 4 (2005) 262-270
39. Kimura R., Miyashita K., Kokubo Y., et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120 2 (2007) 181-186
40. Shikata E., Ieiri I., Ishiguro S., et al. Multiple gene polymorphisms and warfarin sensitivity. Eur J Clin Pharmacol 62 10 (2006) 881-883
41. Tham L.S., Goh B.C., Nafziger A., et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 80 4 (2006) 346-355
42. Vecsler M., Loebstein R., Almog S., et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95 2 (2006) 205-211
43. Wadelius M., Chen L.Y., Eriksson N., et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121 1 (2007) 23-34
44. Anderson J.L., Horne B.D., Stevens S.M., et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116 22 (2007) 2563-2570
45. Caldwell M.D., Berg R.L., Zhang K.Q., et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 5 1 (2007) 8-16
46. Carlquist J.F., Horne B.D., Muhlestein J.B., et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 22 3 (2006) 191-197
47. Gage B., Eby C., Johnson J., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84 (2008) 326-331
48. Gage B.F., Eby C., Milligan P.E., et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91 1 (2004) 87-94
49. Herman D., Locatelli I., Grabnar I., et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 5 3 (2005) 193-202
50. Miao L., Yang J., Huang C., et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63 12 (2007) 1135-1141
51. Voora D., Eby C., Linder M.W., et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 93 4 (2005) 700-705
52. Wen M.S., Lee M., Chen J.J., et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 84 (2008) 83-89